This result is of clinical relevance as blood IL-1β levels are increased in patients with COVID-19 [53,54], and administration of the IL-1 receptor antagonist Anakinra improved outcomes of severe COVID-19 patients [54]. This evidence concerns the gene IL1B and COVID-19.